The activity of the immune system can diminish with age and can be actively impaired by tumor cells or pro-inflammatory cells in the central nervous system during disease.

Plexium is utilizing the DELPhe platform to identify E3 ligase-binding small molecules that will redirect the immune system or increase its function in immunosuppressive environments. With an understanding of the relevant activating and inhibitory signals that impact immune cell function, Plexium identifies small molecules that will restore desired signaling and optimize beneficial immune cell responses.

Although treatment successes have been seen in certain types of solid tumors, several types of aggressive lung and breast cancer have not seen new therapies in over 30 years. These high unmet medical need tumors are a focus of drug discovery at Plexium.

Redirected protein degradation of tumor cell-specific targets will pave the way for safer and more effective cancer therapy. Plexium is utilizing the DELPhe platform to identify E3 ligase-binding small molecules that are designed to target tumor cells while sparing normal cells.